[Federal Register Volume 62, Number 99 (Thursday, May 22, 1997)]
[Notices]
[Pages 28045-28048]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-13427]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Government-Owned Inventions; Availability for Licensing
AGENCY: Office of Technology Transfer, Centers for Disease Control and
Prevention (CDC), Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
The inventions named in this notice are owned by agencies of the
United
[[Page 28046]]
States Government and are available for licensing in the United States
(U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for U.S. companies and may also be
available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to Marjorie
Hunter, Licensing Specialist at the Technology Transfer Office, Centers
for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton
Rd., Atlanta, GA 30333, telephone (404) 639-6271; facsimile (404) 639-
6266. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Methods and Compositions for an Artificial Lung Organ Culture System
Quinn, F. D.; Birkness, K. A.
Filed 23 September 94
Serial No. 08/679,081 (Ref # E-14)
Methods have been developed creating an artificial lung culture
system, comprised of multiple human cell layers, for studying the
passage of pathogens and chemical substances through the organ. The
system is comprised of an endothelial cell layer and an alveolar
epithelial cell layer oriented on either side of, and in direct contact
with, an artificial microporous membrane. This stable culture system
provides a more complex system for study than simple monolayers of
human cells or animal models. The culture system is easily maintained
without the use of antibiotics and is viable for longer periods of time
than other models. (Portfolio: Human Organ, Tissue Culture, Liver.)
Infectious cDNA Clones for Dengue Virus: Strain 16881 and Live
Attenuated Vaccine Derivative, Strain PDK-53
Kinney, R. M.; Gubler, D. J.; Trent, D. W.; Halstead, S. B.; Chang, J.;
Butrapet, S.; Bhamarapravati, N.
Filed 7 June 95
Serial No. 08/483,292 (Ref # E-132-95/0)
A quadravalent vaccine which evokes immunity against all four
serotypes of dengue virus comprising DEN-2 PDK-53 infectious clone
derivative, DEN-2/1, DEN-2/3, or DEN-2/4 viruses, and related methods
of immunization are described in this invention. The invention also
provides a method of cloning and sequencing a cDNA copy of an entire
RNA genome of the PDK-53 vaccine derivative of dengue 2 virus, strain
16681, which can be used to engineer new dengue vaccines as well as
recombinant chimeric viruses. This invention provides a host cell with
multiple constructs of protein encoded by several nucleotide sequences.
(Portfolio: Vector-borne Infectious Diseases, Vaccine, Dengue, Chimeric
Viruses.)
SecA Gene of Mycobacterium Tuberculosis and Related Methods and
Compositions
Quinn, F. D.; Owens, M. H.; King, C. H.
Filed 22 February 95
Serial No. 08/394,646 (Ref # E-066-95/0)
This invention includes an isolated nucleic acid encoding a SecA
protein of Mycobacteria tuberculosis. This nucleic acid can be a native
coding sequence for the SecA protein or any alternative coding sequence
for the SecA protein of M. Tuberculosis. An isolated fragment of the
secA gene that is specific for M. Tuberculosis is also provided. A
purified SecA protein of M. Tuberculosis which comprises the sequence
set forth in the Sequence Listing as SEQ ID NO: 2 is provided.
Fragments of the M. Tuberculosis SecA protein, a purified mutant SecA
protein of M. Tuberculosis, and a purified mutant M. Tuberculosis
expressing the mutant SecA protein are provided in the invention.
The invention provides methods of screening for putative M.
Tuberculosis virulence factors translocated by the SecA protein. In one
example of the method (the method comprises: inhibiting the
translocation ATPase activity of the M. Tuberculosis SecA protein, and
detecting the accumulation of precursor forms of proteins in the
cytoplasm of the M. Tuberculosis cells) the accumulation of a precursor
indicating the presence of a translocation ATPase activity of the M.
Tuberculosis SecA protein can be inhibited by administering an amount
of sodium azide to M. Tuberculosis cells or by mutating the secA gene
so that it produces a non-lethal translocation ATPase deficient M.
Tuberculosis mutant.
Treating HIV Infection by Inhibiting Bcl-2
Sandstrom, P. A.; Folks, T. M.
Filed 29 January 96
Serial No. 08/593,407 (Ref # E-102-
95/0)
This invention provides a method of treating an HIV infection by
inhibiting Bcl-2 expression or activity. This invention also provides a
method of screening for a compound that inhibits HIV replication. This
invention also provides a cell line transfected with a nucleic acid
that encodes Bcl-2, wherein the cell line expresses bcl-2, and the cell
line is infected with HIV. (Portfolio: HIV, AIDS, Viral Infection,
Cellular Biology.)
Methods for Sensitive Detection of Reverse Transcriptase Activity
Heneine, W.; Folks, T. M.; Switzer, W. M.; Yamamoto, S.
Filed 27 January 95
Serial No. 08/379,851 (Ref # E-232-
93/0)
This invention provides a method for detecting a retrovirus in a
biological sample by identifying the presence of the enzyme reverse
transcriptase (RT). This RT assay employs a PCR-based amplification
system to detect a known cDNA product of the RT reaction. This
invention is highly sensitive and specific and requires no knowledge of
viral genomic sequence. Retroviruses that previously would have gone
undetected may now be identified. (Portfolio: PCR, Reverse
Transcriptase, Retrovirus, Diagnosis.)
Nucleotide Sequences of New Hantavirus--``Bayou Virus''
Nichol, S.; Morzunov, S.; Ksiazek, T.; Rollin, P.; Spiropoulou, C.
Filed 17 February 95
Serial No. 08/390,888 (Ref # E-183
-93/2)
Nucleotide sequences of the M and S segments of the Louisiana virus
genome have been identified. Included are several different methods of
detecting the ``Bayou'' hantavirus and isolated nucleic acids specific
for the ``Bayou'' hantavirus. Purified antigenic polypeptides and
antibodies that specifically bind to the ``Bayou'' hantavirus or those
polypeptides are provided. (Portfolio: Hantavirus, Bayou.)
Nucleic Acids of a Novel Hantavirus and Reagents for Detection and
Prevention of Infection. The ``Sin Nombre'' Hantavirus
Rollin, P.; Elliott, L.; Ksiazek, T.; Nichol, S.
Filed 24 June 94
Serial No. 08/569,242 (Ref # E-183-
93/3)
This invention describes a nucleotide sequence for a new
hantavirus, referred to as ``Sin Nombre'' hantavirus, which is the
causative agent of hantavirus pulmonary syndrome. A method of detection
of the ``Sin Nombre'' hantavirus and an associated method of prevention
of infection is provided. The
[[Page 28047]]
``Sin Nombre'' virus strain was previously known as the ``Muerto
Canyon'' hantavirus. (Portfolio: Hantavirus, Diagnosis.)
The Black Creek Canal Strain of Hantavirus and Methods of Detection and
Prevention of Infection Therefrom
Nichol, S. T.; Elliott, L.; Ksiazek, T. G.; Morzunov, S.; Ravkov, E.;
Rollin, P. E.
Filed 17 February 95
Serial No. 08/390,361 (Ref # E-183-
93/4)
The Black Creek Canal strain of hantavirus, which is responsible
for a case of hantavirus Pulmonary Syndrome in Florida, is provided.
The virus was isolated from a rodent and is genetically different at
the nucleotide level from the Muerto Canyon virus. The invention also
provides purified polypeptides encoded by the nucleic acids, purified
antibodies that bind the hantavirus, and describes methods of detection
and prevention. (Portfolio: Hantavirus, Vaccine, Black Creek Canal
Strain.)
Method and Composition for Diagnosing Cat Scratch Disease and Bacillary
Angiomatosis Caused by Rochalimaea Henselae (Now Referred to as
Bartonella Henselae)
Regnery, R. L.; Anderson, B.E.
Patent Issued: 21 March 95
Patent No. 5,399,485 (Ref # E-048-92/0)
This invention provides a method of diagnosing cat scratch disease
and bacillary angiomatosis by detecting the presence of Bartonella
henselae or an immunogenically specific determinant thereof in humans
or animals. Also provided is a vaccine comprising an immunogenic amount
of a nonpathogenic Bartonella henselae and a pharmaceutically
acceptable carrier. (Portfolio: Vaccine, Cat Scratch Disease,
Bartonella.)
Method for Detection of a New Marker Associated With Hepatitis Delta
Virus Infection
Fields, H. A.; Khudyakov, Y.; Favorov, M.
Patent Issued: 29 August 95
Patent No. 5,445,932 (Ref # E-069-92/0)
Reagents and methods for the detection of a marker which is
associated with severe forms of hepatitis delta have been developed.
This invention detects the presence of anti-HDAg' antibodies in a
biological sample. It also describes a vaccine comprised of
immunogenically active HDAg' polypeptides in a pharmaceutically
acceptable carrier. (Portfolio: Hepatitis Delta, Vaccine, Diagnosis.)
DNA Sequence Encoding a Cynomolgus Monkey Hepatitis A Virus Capsid
Protein
Nainan, O. V.; Margolis, H. S.; Robertson, B. H.; Brinton, M. A.;
Ebert, J. W.
Patent Issued: 4 July 95
Patent No. 5,430,135 (Ref # E-089-91/1)
This invention relates to substantially pure preparations of the
cynomolgus monkey hepatitis A viral isolates CY-145 and CY-55/JM-55,
which may be used in the prevention of hepatitis A in animals. This
invention provides a virus that may be adapted in a cell-line suitable
for human vaccine development or may be cloned into an expression
vector in which the cDNA coding for the capsid region of the virus may
provide a virus-like antigen which could substitute for the whole
virus. (Portfolio: Hepatitis A, Diagnosis, Vaccine.)
Nucleic Acid Probes and Methods for Detecting Candida DNA Cells in
Blood
Lot, T. J.; Morrison, C. J.; Reiss, E.; Lasker, B.; Zakroff, S.
Patent Issued: 20 June 95
Patent No. 5,426,027 (Ref # E-118-93/0)
An isolated double-stranded nucleic acid sequence specific for
Candida albicans, as well as ITS2 sequences for C. Parapsilosis, C.
Tropoicalis, C. Glabrata and C. Krusei, is provided. This invention
also contemplates an isolated nucleic acid that specifically hybridizes
with, or selectively amplifies, a nucleic acid of C. albicans. These
sequences may be used in a rapid method of diagnosing systemic
candidiasis in patients by detecting C. albicans in blood samples with
concentration as low as 10 cells per ml. (Portfolio: Nucleic Acid
Sequencing, Candida, Diagnostics.)
Ear Based Hearing Protector/Communication System
Franks, J. R.; Sizemore, C. W.; Dunn,
D. E.
Patent Issued: 20 June 95
Patent No. 5,426,719 (Ref # E-154-91/0)
A combination hearing protector and communication device which may
be incorporated into earmuffs/earplugs has been developed. The system
allows dual channels and does not compromise the noise-reducing
characteristics of normal earmuffs or earplugs. The system incorporates
an independent transmission channel with the wearer having the
possibility of receiving the same channel as other wearers. (Portfolio:
Ear Protection, Communication, Hearing Safety.)
PsaA
Russell, H.; Sampson, J.; O'Connor, S.
Patent Issued: 6 June 95
Patent No. 5,422,427 (Ref # E-157-91/0)
The patent claims a DNA sequence encoding a pneumonacoccal surface
adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial
protein. This sequence may be utilized to relates to produce a PsaA
polypeptide. The sequence may also be utilized to design diagnostics
for measuring the amount of PsaA contained in a sample. Vaccines which
may be efficacious in adults or children may be developed using the
sequence or polypetides. (Portfolio: Vaccine, Diagnosis, Pneumococal
Surface Adhesin A Protein.)
Streptococcus Pneumoniae 37-KDa Surface Adhesin A Protein
Sampson, J.; Russell, H.; Tharpe, J.; Ades, E.; Carlone, G.
Filed 17 September 1996
Serial No.08/715,131 (Ref # E-157-91/4)
This invention provides the isolated nucleic acid encoding the 37-
kDa protein of Streptococcus pneumoniae designated pneumococcal surface
adhesin A protein (PsaA), formerly designated as pneumococcal fimbrial
protein. This invention relates to purified polypetides encoded by the
sequence and a method of measuring the amount of PsaA contained in a
sample. This invention also includes a vaccine that may be efficacious
in adults or children. (Portfolio: Vaccine, Diagnosis, Pneumococal
Surface Adhesin A Protein.)
Use of Human Immortalized Endothelial Cells to Isolate and Propagate
Ehrlichia chaffeensis and Ehrlichia canis
Dawson, J. E.
Patent Issued: 28 March 95
Patent No. 5,401,656 (Ref # E-155-91/0)
This invention provides a purified immortalized human endothelial
cell infected with Ehrlichia Chaffeensis or Ehrlichia canis. The
invention provides a method for simultaneously screening a human
subject for E. Chaffeensis or Rickettsia rickettsii. Also provided is a
method of culturing E. chaffeensis and E. Canis. (Portfolio: Diagnosis,
Ehrlichiosis, Cell Culture.)
Immunoreactive HTLV-I/II and POL Peptides
Lal, R. B.
Patent Issued 3 January 1995
Patent No. 5,378,805 (Ref # E-172-90/0)
This invention relates to a peptide having specific
immunoreactivity to antibodies to HTLV-I, HTLV-II derived from the
structural gene products from groups consisting of Env-1, Env-2,
[[Page 28048]]
Env-5, Gag-1a, and Pol-3. This invention is further directed to an
immunoassay method for the detection of antibodies, a peptide
composition containing these peptides, and a vaccine. (Portfolio: HTLV,
Vaccine, Diagnostics.)
Methods and Compositions for Diagnosing HTLV-1 Associated Myelopathy
and Adult T-Cell Leukemia
Rudolph, D. L.; Lal, R. B.
Patent Issued 30 May 1995
Patent No. 5,420,244 (Ref # E-206-93/0)
This invention provides antigenic peptides derived from
immunodominant epitopes of the HTLV-I tax or rex proteins that are
immunoreactive with antibodies associated with disease in HTLV-I
infected subjects. This invention provides peptides corresponding to
the immunodominant epitopes of the rex regulatory protein of HTLV-I.
This invention provides methods for diagnosing HTLV-I associated
myelopathy. This invention also provides methods for diagnosing adult
T-cell leukemia. (Portfolio: HTLV-I, HIV, Antibodies, HAM [HTLV-I
Associated Myelopathy], T-cell Leukemia, Diagnosis.)
Isolation of Diagnostic Glycoproteins to Taenia Solium, Immunoblot-
assay and Method for the Detection of Human Cysticercosis
Tsang, V. C. W.; Brand, J.; Boyer, A.; Wilson, M.; Schantz, P.;
Maddison, S.
Patent Issued 11 October 94
Patent No. 5,354,660 (Ref # E-185-88/1)
This invention is a method and a kit for diagnosing active human
neurocysticercosis utilizing an immunoblot assay. This method allows
diagnosis of neurocysticercosis by the detection antigens of larval
origin. This invention improves on the specificity and sensitivity of
the disc method achieving 98% sensitivity and 100% specificity. This
allows the detection of antibodies in the serum or cerebrospinal fluid.
(Portfolio: Larval Detection, Taenia solium, Neurocysticercosis,
Diagnosis.)
Exchangeable Template Reaction
Khudyakov, Y.; Fields, H.
Patent Issued: 2 April 96
Patent No. 5,503,995 (Ref # E-184-91/1)
This invention provides a method of making synthetic DNA of any
desired sequence. This invention can be used to make an array of DNA
having specific substitution in a known sequence which are expressed
and screened for improved function. This invention provides a method
for the synthesis of DNA based on a cyclic mechanism of combining
deoxyoligonucleotides. Also included is a kit comprising a series of
unique synthesized single-stranded deoxypolynucleotides which can be
enzymatically treated to form a unique 3' single-stranded protrusion
for selective cyclic hybridization with another unique single-stranded
deoxypolynucleotide of the series.(Portfolio: DNA, DNA Synthesis.)
Sequences of the Hemagglutinins of Recent Strains of Influenza Type B
virus
Rota, P. A.; Hemphill, M. L.
Patent Issued: 20 December 94
Patent No. 5,374,717 (Ref # E-224-92/0)
This invention provides sequence analyses for recent strains of
Influenza Type B virus. This invention also provides a method for
vaccinating a mammal against influenza type B. This invention also
provides a method of detection and diagnosis of an infection with
influenza type B virus. (Portfolio: Virus, Influenza Type B, Vaccine.)
Method for Detecting Isocyanates
Streicher, R. P.
Patent Issued 11 October 94
Patent No. 5,354,689 (Ref # E-215-92/0)
This invention provides a method for detecting the presence of
isocyanate in a sample. Also, the invention provides a method of
quantifying the total isocyanate presence by quantifying the reaction
product. This invention is particularly well-suited to the detection of
isocyanates in air. (Portfolio: Isocyanate, Detection.)
Portable Spirometer With Improved Accuracy
Hankinson, J. L.; Viola, J. C.; Ebeling, T. H.
Patent Issued 8 October 96
Patent No. 5,562,101 (Ref # E-030-92/1)
This invention is a spirometric measurement device with an
arrangement for computation of a dynamic correction factor to
compensate for temperature-related changes. This invention improves the
accuracy by increasing the analog-to-digital conversion resolution, by
modifying the dithering process, and by compensating for the inherent
transducer temperature drift. This invention provides for a multi-
functional, downloadable, flexible spirometric device, that requires no
disassembly with improved quality control. (Portfolio: Spirometric,
Lung Capacity, Respiratory Function.)
Dated: May 16, 1997.
Joseph R. Carter,
Acting Associate Director for Management and Operations, Centers for
Disease Control and Prevention (CDC).
[FR Doc. 97-13427 Filed 5-21-97; 8:45 am]
BILLING CODE 4163-18-P